{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:19:32Z","timestamp":1758269972022},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s11926-005-0019-6","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T11:32:13Z","timestamp":1180783933000},"page":"348-355","source":"Crossref","is-referenced-by-count":6,"title":["Inflammatory neuropathies: an update on evaluation and treatment"],"prefix":"10.1007","volume":"7","author":[{"given":"Lisa D.","family":"Hobson-Webb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Donofrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","volume":"35","author":"Guillain-Barr\u00e9 Syndrome Study Group","year":"1985","unstructured":"Guillain-Barr\u00e9 Syndrome Study Group: Plasmapheresis and acute Guillain-Barr\u00e9 syndrome. Neurology 1985, 35:1096\u20131104.","journal-title":"Neurology"},{"key":"19_CR2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s001340051323","volume":"26","author":"H Esperou","year":"2000","unstructured":"Esperou H, Jars-Guincestre MC, Bolgert F, et al.: Cost-analysis of plasma exchange therapy for the treatment of Guillain-Barr\u00e9 syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 syndrome. Intensive Care Med 2000, 26:1094\u20131100.","journal-title":"Intensive Care Med"},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"RAC Hughes","year":"1997","unstructured":"Hughes RAC, Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group: Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Lancet 1997, 349:225\u2013230.","journal-title":"Lancet"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","volume":"2","author":"French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome","year":"1987","unstructured":"French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome: Efficacy of plasma exchange in Guillain-Barr\u00e9 syndrome: role of replacement fluids. Ann Neurol 1987, 2:753\u2013761.","journal-title":"Ann Neurol"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group","year":"1997","unstructured":"Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group: Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillian-Barr\u00e9 syndrome. Lancet 1997, 349:225\u2013230.","journal-title":"Lancet"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/0140-6736(91)91995-7","volume":"338","author":"RA Hughes","year":"1991","unstructured":"Hughes RA: Ineffectiveness of high dose intravenous methyl-prednisolone in Guillain-Barr\u00e9 syndrome. Lancet 1991, 338:1142.","journal-title":"Lancet"},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ana.410350618","volume":"35","author":"The Dutch Guillain-Barr\u00e9 Study Group","year":"1994","unstructured":"The Dutch Guillain-Barr\u00e9 Study Group: Treatment of Guillain-Barr\u00e9 syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994, 35:749\u2013752.","journal-title":"Ann Neurol"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"R Koningsveld Van","year":"2004","unstructured":"Van Koningsveld R, Schmitz PIM, van der Meche FGA, et al.: Effect of methylprednisolone when added to standard treat-ment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomized trial. Lancet 2004, 363:192\u2013196. A randomized controlled trial demonstrating that IVIg plus methyl-prednisolone is no better than IVIg monotherapy.","journal-title":"Lancet"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/01.WNL.0000092019.53628.88","volume":"61","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Gray IA, Idrissova ZR, et al.: A randomized con-trolled trial of recombinant interferon-beta 1a in Guillain-Barr\u00e9 syndrome. Neurology 2003, 61:1282\u20131284.","journal-title":"Neurology"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMra041347","volume":"352","author":"H K\u00f6ller","year":"2005","unstructured":"K\u00f6ller H, Kieseier BC, Jander S, Hartung H-P: Chronic inflam-matory demyelinating polyneuropathy. N Engl J Med 2005, 352:1343\u20131356. Excellent review of CIDP representing the latest knowledge in the field.","journal-title":"N Engl J Med"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2003-41130","volume":"23","author":"JT Kissel","year":"2003","unstructured":"Kissel JT: The treatment of chronic inflammatory demyelinat-ing polyneuropathy. Semin Neurol 2003, 23:169\u2013179.","journal-title":"Semin Neurol"},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","volume":"11","author":"PJ Dyck","year":"1982","unstructured":"Dyck PJ, O\u2019Brien PC, Oviatt KF, et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136\u2013141.","journal-title":"Ann Neurol"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","volume":"314","author":"PJ Dyck","year":"1986","unstructured":"Dyck PJ, Daube J, O\u2019Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461\u2013465.","journal-title":"N Engl J Med"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1991.00530140113024","volume":"48","author":"PA Doorn Van","year":"1991","unstructured":"Van Doorn PA, Vermeulen M, Brand A, et al.: Intravenous immunoglobulin treatment in patients with chronic inflam-matory demyelinating polyneuropathy. Arch Neurol 1991, 48:217\u2013220.","journal-title":"Arch Neurol"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archneur.62.2.249","volume":"62","author":"G Lopate","year":"2005","unstructured":"Lopate G, Pestronk A, Al-Lozi M: Treatment of chronic inflam-matory demyelinating polyneuropathy with high-dose inter-mittent intravenous methylprednisolone. Arch Neurol 2005, 62:249\u2013254. This 2005 study provides evidence that intermittent intravenous corti-costeroids are as effective as daily oral corticosteroids, but result in fewer complications. This article has the potential to change current treatment of CIDP.","journal-title":"Arch Neurol"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1212\/01.WNL.0000134676.05850.C0","volume":"63","author":"KC Gorson","year":"2004","unstructured":"Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715\u2013717.","journal-title":"Neurology"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-510X(01)00478-6","volume":"185","author":"N Mowzoon","year":"2001","unstructured":"Mowzoon N, Sussman A, Bradley WG: Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflam-matory polyneuropathy and inclusion body myositis. J Neurol Sci 2001, 185:119\u2013122.","journal-title":"J Neurol Sci"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.35.8.1173","volume":"35","author":"PJ Dyck","year":"1985","unstructured":"Dyck PJ, O\u2019Brien P, Swanson C, et al.: Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1985, 35:1173\u20131176.","journal-title":"Neurology"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/(SICI)1097-4598(199804)21:4<454::AID-MUS3>3.0.CO;2-8","volume":"21","author":"MH Barnett","year":"1998","unstructured":"Barnett MH, Pollard JD, Davies L, McLeod JG: Cyclosporin A in resistant chronic inflammatory demyelinating polyradicu-loneuropathy. Muscle Nerve 1998, 21:454\u2013460.","journal-title":"Muscle Nerve"},{"key":"19_CR20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/jnnp.60.2.185","volume":"60","author":"W Mahattanakul","year":"1996","unstructured":"Mahattanakul W, Crawford TO, Griffin JW, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporine-A. J Neurol Neurosurg Psychiatry 1996, 60:185\u2013187.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR21","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1468-1331.2004.00911.x","volume":"11","author":"C Briani","year":"2004","unstructured":"Briani C, Zara G, Zambello R, et al.: Rituximab-responsive CIDP. Euro J Neurol 2004, 11:788\u2013791.","journal-title":"Euro J Neurol"},{"key":"19_CR22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1097-4598(200003)23:3<433::AID-MUS17>3.0.CO;2-O","volume":"23","author":"MN Meriggioli","year":"2000","unstructured":"Meriggioli MN, Rowin J: Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve 2000, 23:433\u2013435.","journal-title":"Muscle Nerve"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.53.1.57","volume":"53","author":"RD Hadden","year":"1999","unstructured":"Hadden RD, Sharrack B, Bensa S, et al.: Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999, 53:57\u201361.","journal-title":"Neurology"},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00019052-200406000-00013","volume":"17","author":"BJ Stern","year":"2004","unstructured":"Stern BJ: Neurological complications of sarcoidosis. Curr Opin Neurol 2004, 17:311\u2013316. A comprehensive, yet succinct, review of neurosarcoidosis, its presen-tation, and treatment.","journal-title":"Curr Opin Neurol"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0022-510X(02)00414-8","volume":"208","author":"JR Shah","year":"2003","unstructured":"Shah JR, Lewis RA: Sarcoidosis of the cauda equina mimicking Guillain-Barr\u00e9 syndrome. J Neurol Sci 2003, 208:113\u2013117.","journal-title":"J Neurol Sci"},{"key":"19_CR26","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1212\/WNL.41.10.1558","volume":"41","author":"G Zuniga","year":"1991","unstructured":"Zuniga G, Ropper AH, Frank J: Sarcoid peripheral neuropathy. Neurology 1991, 41:1558\u20131561.","journal-title":"Neurology"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/WNL.57.5.927","volume":"57","author":"D Ferriby","year":"2001","unstructured":"Ferriby D, de Seze J, Stojkovic T, et al.: Long-term follow-up of neurosarcoidosis. Neurology 2001, 57:927\u2013929.","journal-title":"Neurology"},{"key":"19_CR28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/brain\/awf027","volume":"125","author":"G Said","year":"2002","unstructured":"Said G, Lacroix C, Plant\u00e9-Bordeneuve V, et al.: Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinico-pathological study of 11 patients. Brain 2002, 125:264\u2013275.","journal-title":"Brain"},{"key":"19_CR29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1474-4422(04)00805-1","volume":"3","author":"E Hoitsma","year":"2004","unstructured":"Hoitsma E, Faber CG, Drent M, Sharma OP: Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004, 3:397\u2013407.","journal-title":"Lancet Neurol"},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1378\/chest.124.5.2023","volume":"124","author":"JD Doty","year":"2003","unstructured":"Doty JD, Mazur JE, Judson MA: Treatment of corticosteroid-resistant neurosarcoidosis with a short course cyclophospha-mide regimen. Chest 2003, 124:2023\u20132026.","journal-title":"Chest"},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00415-004-0432-1","volume":"251","author":"M Sollberger","year":"2004","unstructured":"Sollberger M, Fluri F, Baumann T, et al.: Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004, 251:760\u2013761.","journal-title":"J Neurol"},{"key":"19_CR32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mus.10541","volume":"29","author":"D Heaney","year":"2004","unstructured":"Heaney D, Geddes JF, Nagendren K, Swash M: Sarcoid poly-neuropathy responsive to intravenous immunoglobulin. Muscle Nerve 2004, 29:447\u2013450.","journal-title":"Muscle Nerve"},{"key":"19_CR33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/archneur.1992.00530340089023","volume":"49","author":"BJ Stern","year":"1992","unstructured":"Stern BJ, Schofeld SA, Sewell C, et al.: The treatment of neurosarcoidosis with cyclosporine. Arch Neurol 1992, 49:1065\u20131072.","journal-title":"Arch Neurol"},{"key":"19_CR34","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/01.WNL.0000034766.13282.33","volume":"59","author":"JA Pettersen","year":"2002","unstructured":"Pettersen JA, Zochodne DW, Bell RB, et al.: Refractory neuro-sarcoidosis responding to infliximab. Neurology 2002, 59:1660\u20131661.","journal-title":"Neurology"},{"key":"19_CR35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archneur.55.9.1248","volume":"55","author":"OP Sharma","year":"1998","unstructured":"Sharma OP: Effectiveness of chloroquine and hydroxychloro-quine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 1998, 55:1248\u20131254.","journal-title":"Arch Neurol"},{"key":"19_CR36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1259\/bjr\/27963001","volume":"77","author":"F Bruns","year":"2004","unstructured":"Bruns F, Pruemer B, Haverkamp U, Fischedick AR: Neurosar-coidosis: an unusual indication for radiotherapy. Br J Radiol 2004, 77:777\u2013779.","journal-title":"Br J Radiol"},{"key":"19_CR37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mus.20100","volume":"30","author":"T Kuntzer","year":"2004","unstructured":"Kuntzer T, Antoine J-C, Steck AJ: Clinical features and patho-physiological basis of sensory neuronopathies (gangliono-pathies). Muscle Nerve 2004, 30:255\u2013268. A detailed presentation of the ganglionopathies useful for anyone treating patients with these disorders.","journal-title":"Muscle Nerve"},{"key":"19_CR38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.10402","volume":"28","author":"PD Donofrio","year":"2003","unstructured":"Donofrio PD: Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve 2003, 28:273\u2013292. A detailed, comprehensive review of the inflammatory neuropathies with information on the history, pathophysiology, clinical findings, and treatment of each disorder.","journal-title":"Muscle Nerve"},{"key":"19_CR39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/mus.10470","volume":"28","author":"KC Gorson","year":"2003","unstructured":"Gorson KC, Ropper AH: Positive salivary gland biopsy, Sj\u00f6gren syndrome, and neuropathy: clinical implications. Muscle Nerve 2003, 28:553\u2013560.","journal-title":"Muscle Nerve"},{"key":"19_CR40","first-page":"1552","volume":"30","author":"J Font","year":"2003","unstructured":"Font J, Ramos-Casals M, de la Red G, et al.: Pure sensory neuro-pathy in primary Sj\u00f6gren\u2019s syndrome. Long-term prospective followup and review of the literature. J Rheumatol 2003, 30:1552\u20131557.","journal-title":"J Rheumatol"},{"key":"19_CR41","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/jnnp.60.6.699","volume":"60","author":"JA Molina","year":"1996","unstructured":"Molina JA, Benito-Leon J, Bermejo F, et al.: Intravenous immunoglobulin therapy in sensory neuropathy associated with Sj\u00f6gren\u2019s syndrome. J Neurol Neurosurg Psychiatry 1996, 60:699.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1212\/WNL.51.2.650-b","volume":"51","author":"J Pascual","year":"1998","unstructured":"Pascual J, Cid C, Berciano J: High-dose IV immunoglobulin for peripheral neuropathy associated with Sj\u00f6gren\u2019s syndrome. Neurology 1998, 51:650\u2013651.","journal-title":"Neurology"},{"key":"19_CR43","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000052142","volume":"45","author":"WH Chen","year":"2001","unstructured":"Chen WH, Yeh JH, Chiu HC: Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sj\u00f6gren\u2019s syn-drome. Eur Neurol 2001, 45:270\u2013274.","journal-title":"Eur Neurol"},{"key":"19_CR44","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1212\/WNL.51.5.1451","volume":"51","author":"M Asahina","year":"1998","unstructured":"Asahina M, Kuwabara S, Asahina M, et al.: D-Penicillamine treatment for chronic sensory ataxic neuropathy associated with Sj\u00f6gren\u2019s syndrome. Neurology 1998, 51:1451\u20131453.","journal-title":"Neurology"},{"key":"19_CR45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jnnp.2004.049502","volume":"76","author":"S Yamada","year":"2005","unstructured":"Yamada S, Mori K, Matsuo K, et al.: Interferon alfa treatment for Sj\u00f6gren\u2019s syndrome associated neuropathy. J Neurol Neurosurg Psychiatry 2005, 76:576\u2013578.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR46","first-page":"301","volume":"3","author":"N Latov","year":"1988","unstructured":"Latov N, Hays AP, Sherman WH: Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 1988, 3:301\u2013332.","journal-title":"Crit Rev Neurobiol"},{"key":"19_CR47","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1212\/WNL.45.8.1577","volume":"45","author":"G Blume","year":"1995","unstructured":"Blume G, Pestronk A, Goodnough LT: Anti-MAG neuropathy associated polyneuropathies: improvement following immuno-therapy with monthly plasma exchange and IV cyclophospha-mide. Neurology 1995, 45:1577\u20131580.","journal-title":"Neurology"},{"key":"19_CR48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/mus.20230","volume":"31","author":"G Isoardo","year":"2005","unstructured":"Isoardo G, Migliaretti G, Ciaramitaro P, et al.: Differential diagnosis of chronic dysimmune demyelinating polyneurop-athies with and without anti-MAG antibodies. Muscle Nerve 2005, 31:52\u201358.","journal-title":"Muscle Nerve"},{"key":"19_CR49","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/mus.1069","volume":"24","author":"KC Gorson","year":"2001","unstructured":"Gorson KC, Ropper AH, Weinberg DH, Weinstein R: Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001, 24:778\u2013786. Noteworthy case series of 24 patients that reports patients\u2019 responses to various immunotherapies.","journal-title":"Muscle Nerve"},{"key":"19_CR50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00415-004-0323-5","volume":"251","author":"A Czaplinski","year":"2004","unstructured":"Czaplinski A, Steck AJ: Immune mediated neuropathies: an update on therapeutic strategies. J Neurol 2004, 251:127\u2013137.","journal-title":"J Neurol"},{"key":"19_CR51","first-page":"91","volume":"83","author":"JN Rodriguez","year":"1998","unstructured":"Rodriguez JN, Fernandez-Jurado A, Martino ML, Prados D: Waldenstr\u00f6m\u2019s macroglobulinemia complicated with acute myeloid leukemia. Report of a case and review of the literature. Haemetologica 1998, 83:91\u201392.","journal-title":"Haemetologica"},{"key":"19_CR52","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.66.5.575","volume":"66","author":"HC Wilson","year":"1999","unstructured":"Wilson HC, Lunn MP, Schey S, Hughes RA: Successful treate-ment of IgM paraproteinemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999, 66:575\u2013580.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR53","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.2002.09.039","volume":"20","author":"MA Dimopoulos","year":"2002","unstructured":"Dimopoulos MA, Zervas C, Zomas A, et al.: Treatment of Waldenstr\u00f6m\u2019s macroglobulinemia with rituximab. J Clin Oncol 2002, 20:2037\u20132333.","journal-title":"J Clin Oncol"},{"key":"19_CR54","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","volume":"27","author":"S Renaud","year":"2003","unstructured":"Renaud S, Gregor M, Fuhr P, et al.: Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003, 27:611\u2013615.","journal-title":"Muscle Nerve"},{"key":"19_CR55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.clinph.2004.07.012","volume":"116","author":"SJ Oh","year":"2005","unstructured":"Oh SJ, G\u00fcrtekin Y, Dropcho EJ, et al.: Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophys 2005, 116:28\u201334. This clinical and electrophysiological study of 16 patients with anti-Hu antibody neuropathy provides the latest information on the presentation and outcome of anti-Hu neuropathy.","journal-title":"Clin Neurophys"},{"key":"19_CR56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00415-002-0706-4","volume":"249","author":"PS Smitt","year":"2002","unstructured":"Smitt PS, Grefkens J, de Leeuw B, et al.: Survival and out-come in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis\/sensory neuronopathy. J Neurol 2002, 249:745\u2013753.","journal-title":"J Neurol"},{"key":"19_CR57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.410440620","volume":"44","author":"JL Molinuevo","year":"1998","unstructured":"Molinuevo JL, Graus F, Serrano C, et al.: Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998, 44:976\u2013980.","journal-title":"Ann Neurol"},{"key":"19_CR58","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/(SICI)1097-4598(199712)20:12<1576::AID-MUS13>3.0.CO;2-Z","volume":"20","author":"SJ Oh","year":"1997","unstructured":"Oh SJ, Dropcho EJ, Claussen GC: Anti-Hu associated paraneo-plastic sensory neuronopathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve 1997, 20:1576\u20131582.","journal-title":"Muscle Nerve"},{"key":"19_CR59","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","volume":"68","author":"F Keime-Gubert","year":"2000","unstructured":"Keime-Gubert F, Grgaus F, Fleury A, et al.: Treatment of para-neoplastic neurological syndromes with antineuronal anti-bodies (anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylpredniso-lone. J Neurol Neurosurg Psychiatry 2000, 68:479\u2013482.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00415-005-0833-9","volume":"252","author":"G Said","year":"2005","unstructured":"Said G, Lacroix C: Primary and secondary vasculitic neurop-athy. J Neurol 2005, 252:633\u2013641.","journal-title":"J Neurol"},{"key":"19_CR61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.bor.0000145518.91595.2f","volume":"17","author":"C Pagnoux","year":"2004","unstructured":"Pagnoux C, Guillevin L: Peripheral neuropathy in systemic vasculitides. Curr Opin Rheumatol 2004, 17:41\u201348.","journal-title":"Curr Opin Rheumatol"},{"key":"19_CR62","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2008-1040862","volume":"18","author":"RK Olney","year":"1998","unstructured":"Olney RK: Neuropathies associated with connective tissue disease. Semin Neurol 1998, 18:63\u201372.","journal-title":"Semin Neurol"},{"key":"19_CR63","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1034\/j.1600-0404.2001.103006386.x","volume":"103","author":"R Omdal","year":"2001","unstructured":"Omdal R, L\u00f8seth S, Torbergsen T, et al.: Peripheral neuropathy in systemic lupus erythematosus \u2014 a longitudinal study. Acta Neurol Scand 2001, 103:386\u2013391.","journal-title":"Acta Neurol Scand"},{"key":"19_CR64","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/art.1780381114","volume":"38","author":"X Puechal","year":"1995","unstructured":"Puechal X, Said G, Hilliquin P, et al.: Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis A clinico-pathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995, 38:1618\u20131629.","journal-title":"Arthritis Rheum"},{"key":"19_CR65","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.10922","volume":"49","author":"L Guillevin","year":"2003","unstructured":"Guillevin L, Cohen P, Mahr A, et al.: Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognostic factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003, 49:93\u2013100.","journal-title":"Arthritis Rheum"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-005-0019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-005-0019-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-005-0019-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:47:16Z","timestamp":1559422036000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-005-0019-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s11926-005-0019-6","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}